Strong effects of the ABCA1 agonist CS6253 on Amyloidβ42/40 ratio and lipoproteins in cynomolgus monkeys
Background ATI has discovered a novel molecule, CS6253, for hereditary Apolipoprotein E4 (ApoE4) associated Alzheimer’s disease (AD), which is highly differentiated from other molecules in development by its focus on cholesterol transport. CS6253 is a 26mer peptide optimized for ATP binding cassette...
Saved in:
Published in | Alzheimer's & dementia Vol. 18; no. S10 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.12.2022
|
Online Access | Get full text |
Cover
Loading…
Abstract | Background
ATI has discovered a novel molecule, CS6253, for hereditary Apolipoprotein E4 (ApoE4) associated Alzheimer’s disease (AD), which is highly differentiated from other molecules in development by its focus on cholesterol transport. CS6253 is a 26mer peptide optimized for ATP binding cassette transporter A1 (ABCA1) mediated cholesterol efflux, in the brain a rate‐limiting step in cholesterol transport from cells to ApoE. ABCA1 activity, as well as CS6253 in AD mouse models, is associated with improvement in AD pathology.
In preparation for human studies, we investigated the effects of the ABCA1 agonist peptide CS6253 on amyloid‐β peptides (Aβ) and lipoproteins in plasma and cerebrospinal fluid (CSF) of cynomolgus monkeys, a species with amyloid and lipoprotein metabolism similar to humans.
Methods
CS6253 peptide was injected intravenously to cynomolgus monkeys at various doses in three different studies, 1) a pharmacokinetics (PK) study, 2) a dose‐range finding (DRF) study, and 3) a 30‐day Good Laboratory Practice (GLP) toxicology study. Plasma and CSF samples were collected at several time points before and after treatment. Levels of cholesterol, triglyceride (TG), lipoprotein particles, apolipoproteins, and Aβ were measured using ELISA, ion‐mobility analysis, and asymmetric flow field flow fractionation (AF4). The relationship between the change in levels of these biomarkers was analyzed using multiple linear regression models and linear mixed‐effects models.
Results
CS6253 intravenous injection, within minutes, induced an increase in small, plasma high‐density lipoprotein (HDL) particles. Plasma TG, ApoE, and Aβ42/40 ratio were transiently increased following CS‐6253 intravenous injection, and a non‐significant decrease in CSF APP and Aβ42 was observed. CS‐6253 in plasma displaced ApoE from HDL to intermediate‐density‐ and low density‐lipoprotein (IDL/LDL) sized particles paralleled by transient reductions in total cholesterol and HDL‐cholesterol. In contrast to plasma, CS6253 had no effect on the assessed CSF apolipoproteins or lipids.
Conclusions
In cynomolgus monkeys administration of the ABCA1 agonist CS6253 transiently increased plasma ApoE and TGs which was paralleled by plasma Aβ42/40 ratio increase, providing a strong rationale for following these markers in ensuing human studies. |
---|---|
AbstractList | Background
ATI has discovered a novel molecule, CS6253, for hereditary Apolipoprotein E4 (ApoE4) associated Alzheimer’s disease (AD), which is highly differentiated from other molecules in development by its focus on cholesterol transport. CS6253 is a 26mer peptide optimized for ATP binding cassette transporter A1 (ABCA1) mediated cholesterol efflux, in the brain a rate‐limiting step in cholesterol transport from cells to ApoE. ABCA1 activity, as well as CS6253 in AD mouse models, is associated with improvement in AD pathology.
In preparation for human studies, we investigated the effects of the ABCA1 agonist peptide CS6253 on amyloid‐β peptides (Aβ) and lipoproteins in plasma and cerebrospinal fluid (CSF) of cynomolgus monkeys, a species with amyloid and lipoprotein metabolism similar to humans.
Methods
CS6253 peptide was injected intravenously to cynomolgus monkeys at various doses in three different studies, 1) a pharmacokinetics (PK) study, 2) a dose‐range finding (DRF) study, and 3) a 30‐day Good Laboratory Practice (GLP) toxicology study. Plasma and CSF samples were collected at several time points before and after treatment. Levels of cholesterol, triglyceride (TG), lipoprotein particles, apolipoproteins, and Aβ were measured using ELISA, ion‐mobility analysis, and asymmetric flow field flow fractionation (AF4). The relationship between the change in levels of these biomarkers was analyzed using multiple linear regression models and linear mixed‐effects models.
Results
CS6253 intravenous injection, within minutes, induced an increase in small, plasma high‐density lipoprotein (HDL) particles. Plasma TG, ApoE, and Aβ42/40 ratio were transiently increased following CS‐6253 intravenous injection, and a non‐significant decrease in CSF APP and Aβ42 was observed. CS‐6253 in plasma displaced ApoE from HDL to intermediate‐density‐ and low density‐lipoprotein (IDL/LDL) sized particles paralleled by transient reductions in total cholesterol and HDL‐cholesterol. In contrast to plasma, CS6253 had no effect on the assessed CSF apolipoproteins or lipids.
Conclusions
In cynomolgus monkeys administration of the ABCA1 agonist CS6253 transiently increased plasma ApoE and TGs which was paralleled by plasma Aβ42/40 ratio increase, providing a strong rationale for following these markers in ensuing human studies. Abstract Background ATI has discovered a novel molecule, CS6253, for hereditary Apolipoprotein E4 ( ApoE4 ) associated Alzheimer’s disease (AD), which is highly differentiated from other molecules in development by its focus on cholesterol transport. CS6253 is a 26mer peptide optimized for ATP binding cassette transporter A1 (ABCA1) mediated cholesterol efflux, in the brain a rate‐limiting step in cholesterol transport from cells to ApoE. ABCA1 activity, as well as CS6253 in AD mouse models, is associated with improvement in AD pathology. In preparation for human studies, we investigated the effects of the ABCA1 agonist peptide CS6253 on amyloid‐β peptides (Aβ) and lipoproteins in plasma and cerebrospinal fluid (CSF) of cynomolgus monkeys, a species with amyloid and lipoprotein metabolism similar to humans. Methods CS6253 peptide was injected intravenously to cynomolgus monkeys at various doses in three different studies, 1) a pharmacokinetics (PK) study, 2) a dose‐range finding (DRF) study, and 3) a 30‐day Good Laboratory Practice (GLP) toxicology study. Plasma and CSF samples were collected at several time points before and after treatment. Levels of cholesterol, triglyceride (TG), lipoprotein particles, apolipoproteins, and Aβ were measured using ELISA, ion‐mobility analysis, and asymmetric flow field flow fractionation (AF4). The relationship between the change in levels of these biomarkers was analyzed using multiple linear regression models and linear mixed‐effects models. Results CS6253 intravenous injection, within minutes, induced an increase in small, plasma high‐density lipoprotein (HDL) particles. Plasma TG, ApoE, and Aβ42/40 ratio were transiently increased following CS‐6253 intravenous injection, and a non‐significant decrease in CSF APP and Aβ42 was observed. CS‐6253 in plasma displaced ApoE from HDL to intermediate‐density‐ and low density‐lipoprotein (IDL/LDL) sized particles paralleled by transient reductions in total cholesterol and HDL‐cholesterol. In contrast to plasma, CS6253 had no effect on the assessed CSF apolipoproteins or lipids. Conclusions In cynomolgus monkeys administration of the ABCA1 agonist CS6253 transiently increased plasma ApoE and TGs which was paralleled by plasma Aβ42/40 ratio increase, providing a strong rationale for following these markers in ensuing human studies. |
Author | Kerman, Bilal E. Meuret, Cristiana Kuklenyik, Zsuzsanna Yassine, Hussein N. Zetterberg, Henrik Xian, Haotian Smadi, Sabrina Noveir, Sassan D Martinez, Ashley E. Johansson, Johannes Johansson, Jan O. Parks, Bryan A |
Author_xml | – sequence: 1 givenname: Bilal E. surname: Kerman fullname: Kerman, Bilal E. email: kerman@usc.edu organization: USC Keck School of Medicine – sequence: 2 givenname: Sassan D surname: Noveir fullname: Noveir, Sassan D organization: Keck School of Medicine ‐ University of Southern California – sequence: 3 givenname: Haotian surname: Xian fullname: Xian, Haotian organization: Keck School of Medicine ‐ University of Southern California – sequence: 4 givenname: Cristiana surname: Meuret fullname: Meuret, Cristiana organization: University of Southern California – sequence: 5 givenname: Sabrina surname: Smadi fullname: Smadi, Sabrina organization: University of Southern California – sequence: 6 givenname: Ashley E. surname: Martinez fullname: Martinez, Ashley E. organization: University of Southern California – sequence: 7 givenname: Johannes surname: Johansson fullname: Johansson, Johannes organization: Artery Therapeutics, Inc – sequence: 8 givenname: Henrik surname: Zetterberg fullname: Zetterberg, Henrik organization: UCL Institute of Neurology – sequence: 9 givenname: Bryan A surname: Parks fullname: Parks, Bryan A organization: Centers for Disease Control and Prevention – sequence: 10 givenname: Zsuzsanna surname: Kuklenyik fullname: Kuklenyik, Zsuzsanna organization: Centers for Disease Control and Prevention – sequence: 11 givenname: Jan O. surname: Johansson fullname: Johansson, Jan O. organization: Artery Therapeutics, Inc – sequence: 12 givenname: Hussein N. surname: Yassine fullname: Yassine, Hussein N. organization: USC Keck School of Medicine |
BookMark | eNp9kL1OwzAYRS1UJFpg4Qk8I6X97NixPYaIP6kSQzuxRG5iF0NiV3YQCo_Fg_BMFLViZLp3OPcOZ4YmPniD0BWBOQGgC919zqGQRKoTNCWc04xToSZ_vYAzNEvpFYCBJHyK3GqIwW-xsdY0Q8LB4uHF4PKmKgnW2-BdGnC1KijPcfC47McuuPb7i9EFAxz14ALWvsWd24VdDINxPmHncTP60Idu-55wH_ybGdMFOrW6S-bymOdofXe7rh6y5dP9Y1Uus0YIlTGmpLRSMN2wttGFETqXraGGC2bzXFNQ1m42ANBKMKJpiRA5KKI21CrLeX6Org-3TQwpRWPrXXS9jmNNoP51VO8d1QdHe5gc4A_XmfEfsi6Xz8fND5YDawc |
ContentType | Journal Article |
Copyright | 2022 the Alzheimer's Association. |
Copyright_xml | – notice: 2022 the Alzheimer's Association. |
DBID | AAYXX CITATION |
DOI | 10.1002/alz.068189 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1552-5279 |
EndPage | n/a |
ExternalDocumentID | 10_1002_alz_068189 ALZ068189 |
Genre | article |
GroupedDBID | --- --K --M .~1 0R~ 1B1 1OC 1~. 1~5 24P 33P 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 8FI 8FJ 8P~ AACTN AAEDT AAHHS AAIKJ AAKOC AALRI AANLZ AAOAW AAXLA AAXUO ABBQC ABCQJ ABCUV ABIVO ABJNI ABMAC ABMZM ABUWG ACCFJ ACCZN ACGFS ACGOF ACPOU ACXQS ADBBV ADBTR ADEZE ADHUB ADKYN ADMUD ADPDF ADVLN ADZMN ADZOD AEEZP AEIGN AEKER AENEX AEQDE AEUYR AEVXI AFKRA AFTJW AGHFR AGUBO AGWIK AGYEJ AITUG AIURR AIWBW AJBDE AJOXV AJRQY AKRWK ALMA_UNASSIGNED_HOLDINGS ALUQN AMFUW AMRAJ AMYDB ANZVX AZQEC BENPR BFHJK BLXMC C45 CCPQU DCZOG EBS EJD EMOBN EO8 EO9 EP2 EP3 F5P FDB FEDTE FIRID FNPLU FYUFA G-Q GBLVA HMCUK HVGLF HX~ HZ~ IHE J1W K9- LATKE LEEKS M0R M41 MO0 MOBAO N9A NAPCQ O-L O9- OAUVE OVD OVEED OZT P-8 P-9 P2P PC. PGMZT PIMPY PSYQQ Q38 QTD RIG ROL RPM RPZ SDF SDG SEL SES SSZ SUPJJ T5K TEORI UKHRP ~G- AAYXX CITATION |
ID | FETCH-LOGICAL-c779-44988f874ac4dca6e7a38de2e574f33a209ffbb000d80e7cd17730919b2f9f553 |
ISSN | 1552-5260 |
IngestDate | Fri Aug 23 03:35:36 EDT 2024 Sat Aug 24 00:53:19 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | S10 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c779-44988f874ac4dca6e7a38de2e574f33a209ffbb000d80e7cd17730919b2f9f553 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1002_alz_068189 wiley_primary_10_1002_alz_068189_ALZ068189 |
PublicationCentury | 2000 |
PublicationDate | December 2022 2022-12-00 |
PublicationDateYYYYMMDD | 2022-12-01 |
PublicationDate_xml | – month: 12 year: 2022 text: December 2022 |
PublicationDecade | 2020 |
PublicationTitle | Alzheimer's & dementia |
PublicationYear | 2022 |
SSID | ssj0040815 |
Score | 2.3964128 |
Snippet | Background
ATI has discovered a novel molecule, CS6253, for hereditary Apolipoprotein E4 (ApoE4) associated Alzheimer’s disease (AD), which is highly... Abstract Background ATI has discovered a novel molecule, CS6253, for hereditary Apolipoprotein E4 ( ApoE4 ) associated Alzheimer’s disease (AD), which is... |
SourceID | crossref wiley |
SourceType | Aggregation Database Publisher |
Title | Strong effects of the ABCA1 agonist CS6253 on Amyloidβ42/40 ratio and lipoproteins in cynomolgus monkeys |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Falz.068189 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLVKZ8MGgQAxvGQJ2FClkyZ2HC_bUFQhBhZTUMUmih2nRMoko06LRL-Br-FD-CauH03CUwybKHKcKPE9uW_fi9DTmJOJz0XhFUwyj4iQeIKGyqNM5FEhCl5EeoPz6Zto8Y68WtHVYPCll7W024qx3P92X8n_UBXGgK56l-wVKNs-FAbgHOgLR6AwHP-Jxmfaj73u52SYjSKzZDoZZetGF8UdJWdge4Q6JjA9B-Mc3jGZP5uByNTtiPyRAYCJIFTlRWOqNpQ2t1x-rpvzplrvdLucGv71y74iO632H1VpWq-wS4Of3Dgay6xj4RvnXZ2Vla5ePG4dz80nVdp-X6C6A4Nps45Xpb1jkTXbHm5P1W5jgyaJ40lZ31sRBL3MD8dgqTZ-bQ-BseqP2aYyP3FlK5NbifULw7cFZLNqP_Yj0D14J9YOofx2Fv3zPFsA-PUHe-0aOoKXoXSIjt6-n89fHCQ7AfWJmvq77hvacrfBSffkHxScvsFjNJblTXTDmRp4anFzCw1UfRuVFjPYYQY3BQbMYIMZ7DCDLWZwU2OHmW9fSXBCfGzQggEtuI8WXNa4Qwt2aLmDli_ny2ThuXYbnmSMe4TwOC5iRjJJcplFimVhnKtAUUaKMMwCnxeF0EpjHvuKyXzCQDrwCRcB_NGUhnfRsG5qdQ9hGQVCcEnhJl0OMuKU5WaalExHoo_Rk8MSpRe2qEpqy2cHKSxkahfyGD03q_eXKWlLs_tXmfwAXe-w-RANt5udegS65VY8diT_DmildIg |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Ovid |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Strong+effects+of+the+ABCA1+agonist+CS6253+on+Amyloid%CE%B242%2F40+ratio+and+lipoproteins+in+cynomolgus+monkeys&rft.jtitle=Alzheimer%27s+%26+dementia&rft.au=Kerman%2C+Bilal+E.&rft.au=Noveir%2C+Sassan+D&rft.au=Xian%2C+Haotian&rft.au=Meuret%2C+Cristiana&rft.date=2022-12-01&rft.issn=1552-5260&rft.eissn=1552-5279&rft.volume=18&rft.epage=n%2Fa&rft_id=info:doi/10.1002%2Falz.068189&rft.externalDBID=10.1002%252Falz.068189&rft.externalDocID=ALZ068189 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1552-5260&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1552-5260&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1552-5260&client=summon |